PSA/KLK3/Kallikrein 3/Prostate Specific Antigen Double Nickase Plasmid (h): sc-400448-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PSA/KLK3/Kallikrein 3/Prostate Specific Antigen Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- PSA/KLK3/Kallikrein 3/Prostate Specific Antigen Double Nickase Plasmid (h) and PSA/KLK3/Kallikrein 3/Prostate Specific Antigen Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting KLK3. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PSA/KLK3/Kallikrein 3/Prostate Specific Antigen Antibody (A67-B/E3): sc-7316
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PSA/KLK3/Kallikrein 3/Prostate Specific Antigen Double Nickase Plasmid (h) | sc-400448-NIC | 20 µg | $410.00 | |||
PSA/KLK3/Kallikrein 3/Prostate Specific Antigen Double Nickase Plasmid (h2) | sc-400448-NIC-2 | 20 µg | $410.00 |
KLK3 encodes prostate-specific antigen (PSA), a secreted serine protease of the kallikrein family that contributes to proteolytic processing of seminal plasma proteins and modulation of the extracellular protease network. PSA/KLK3 activity interfaces with peptide cleavage cascades and extracellular matrix remodeling processes that can influence epithelial differentiation and stromal–epithelial interactions in the prostate microenvironment. KLK3 expression is strongly regulated by androgen receptor signaling, linking it to hormone-responsive transcriptional programs and prostate lineage biology. Dysregulated KLK3 expression and altered protease activity are widely studied in prostate disease contexts, including tumor-associated changes in secretion, differentiation state, and microenvironmental remodeling.
PSA/KLK3/Kallikrein 3/Prostate Specific Antigen Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the KLK3 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within KLK3. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt KLK3 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of KLK3-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.